Oct 24, 2022Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society - Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the...
Sep 11, 2022Acceptance in Major Peer-Reviewed Journals of two Landmark Pre-Clinical StudiesAlpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and...
Sep 6, 2022Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial OfficerJERUSALEM, September 1, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation...
Aug 31, 2022Alpha Tau Medical to Participate in Upcoming September Investor Conferences JERUSALEM, August 30, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer...
Aug 26, 2022Alpha Tau Medical Announces Second Quarter 2022 - Financial Results and Provides Corporate Update-Received FDA Conditional Investigational Device Exemption (IDE), whose conditions have since been satisfied, to initiate a pivotal trial...